Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global bioabsorbable stents market size was valued at USD 1.29 billion in 2024 and is projected to reach USD 7.02 billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 27.9% during the forecast period.
Bioabsorbable stents are medical devices implanted into blood vessels to treat blockages while being gradually absorbed by the body, eliminating permanent implants. This technology primarily addresses coronary and peripheral arterial diseases through temporary scaffolding that dissolves after healing.
Market growth is driven by increasing cardiovascular disease prevalence, technological advancements in biodegradable materials, and growing preference for minimally invasive procedures. According to American Heart Association 2023 data, cardiovascular diseases cause approximately 18.6 million deaths annually worldwide, creating substantial demand for advanced treatment options.
North America dominates the market with 93% market share, attributed to high healthcare expenditure, advanced healthcare infrastructure, and early adoption of innovative medical technologies. Europe follows with approximately 2% market share, showing strong potential for future growth.
Key market players include Abbott Vascular, Boston Scientific, Kyoto Medical Planning Co., Ltd, Elixir, and Arterial Remodeling Technologies, with the top three companies collectively holding 96% market share. These companies focus on product innovation, strategic collaborations, and geographic expansion to strengthen their market positions.
Rising Prevalence of Coronary Artery Disease
The global increase in cardiovascular diseases, particularly coronary artery disease, has created substantial demand for advanced treatment options. With over 17.9 million deaths annually attributed to cardiovascular conditions, the need for effective interventional tools like bioabsorbable stents continues to grow exponentially across both developed and emerging markets.
Advancements in Biocompatible Materials
Recent breakthroughs in polymer science and material engineering have enabled the development of next-generation bioabsorbable stents that offer superior performance while minimizing adverse reactions. These innovations include improved drug-elution technologies that enhance healing while maintaining structural integrity during the critical healing period.
The global bioabsorbable stent market is projected to reach $4.3 billion by 2028, growing at a CAGR of 12.7%
Healthcare systems worldwide are increasingly adopting bioabsorbable stents as standard care for certain indications, particularly in percutaneous coronary interventions where permanent metallic implants may not be ideal for younger patients or specific lesion types.
MARKET CHALLENGES
High Development and Regulatory Costs
The development and clinical testing of bioabsorbable stents requires substantial investment, often exceeding $100 million per product, creating significant barriers to entry for smaller manufacturers. Additionally, the stringent regulatory approval process across different regions adds significant time and resource commitments that smaller companies struggle to manage effectively.
Other Challenges
Technical Complexity and Learning Curve
The implantation technique for bioabsorbable stents differs significantly from traditional metallic stents, requiring specialized training and limiting rapid adoption across all healthcare facilities. This creates a temporary market limitation until sufficient numbers of interventional cardiologists become proficient with the new technology.
Limited Long-Term Clinical Data
Despite promising mid-term results, the complete bioabsorption process typically takes 2-3 years, making long-term data (5-10 years) relatively scarce compared to traditional metallic stents. This creates hesitation among some practitioners who prefer solutions with longer track records, particularly for older patient populations where long-term outcomes are critically important.
Emerging Markets and Untapped Potential
Developing regions with rapidly developing healthcare infrastructure represent significant growth opportunities. Countries across Asia, Latin America, and Africa are investing heavily in advanced cardiovascular care, creating new markets for bioabsorbable stent technology where traditional options may be less accessible or appropriate for specific patient demographics.
Medical tourism hubs in countries like Thailand, Malaysia, and Brazil are increasingly offering advanced bioabsorbable stent procedures, attracting international patients and creating cross-border market expansion opportunities that were previously unavailable through traditional healthcare channels.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Polymer-based Stents dominate due to superior biocompatibility and complete absorption, while metal-based variants face challenges with long-term metal ion release and patient monitoring requirements, driving preference toward bioabsorbable polymer solutions. |
| By Application |
|
Coronary Artery Disease commands the largest share as bioabsorbable stents address the limitations of permanent implants in coronary applications, offering reduced long-term complication risks and eliminating the need for lifelong antiplatelet therapy that traditional metal stents require, making them particularly valuable in high-risk coronary interventions. |
| By End User |
|
Hospitals lead due to their comprehensive cardiac care infrastructure, advanced catheterization laboratories, and ability to handle complex interventional cardiology procedures that require both implantation expertise and post-operative monitoring capabilities for bioabsorbable stent patients. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Abbott Laboratories leads the bioabsorbable stents market with their Absorb GT1 Bioresorbable Vascular Scaffold System, which has received extensive clinical validation and regulatory approvals across multiple regions. The company's strong R&D investments and established distribution network enable them to maintain a dominant market position.
Medtronic follows closely with their Resolute Onyx DES, though their focus has been shifting toward next-generation bioabsorbable materials. Boston Scientific's Synergy stent platform demonstrates strong competition in the European market, leveraging their established cardiology division.
Biotronik and Terumo Corporation have significantly expanded their manufacturing capacities to meet growing demand, particularly in the Asia-Pacific region. Both companies have opened new production facilities in the past 18 months, increasing global production capacity by approximately 15%.
Strategic partnerships continue to shape the competitive landscape, with several players collaborating with academic institutions for next-generation material research. Kyoto Medical and MicroPort Scientific have recently announced joint development programs focusing on improved polymer compositions and enhanced drug-elution capabilities.
List of Key Bioabsorbable Stents Companies ProfiledAbbott Laboratories (United States)
Medtronic plc (Ireland)
Boston Scientific Corporation (United States)
Biotronik SE & Co. KG (Germany)
Terumo Corporation (Japan)
Biosensors International Group Ltd. (Singapore)
Kyoto Medical Planning Co., Ltd. (Japan)
The global bioabsorbable stents market is experiencing significant growth due to increasing preference for minimally invasive surgical procedures. These stents offer the advantage of temporary scaffolding that dissolves after the healing process, reducing long-term complications and eliminating the need for surgical removal. This trend is particularly prominent in coronary artery disease treatments, where bioabsorbable stents are becoming the preferred choice over permanent metal stents.
Other TrendsTechnological Advancements in Material Science
Recent advancements in polymer technology have significantly improved the safety and efficacy profiles of bioabsorbable stents. Manufacturers are developing novel bioresorbable materials with optimized degradation rates that match the natural healing process of blood vessels. These innovations include improved drug-eluting capabilities that prevent restenosis while minimizing inflammatory responses. The latest generation of stents also features enhanced radiopacity for better visibility during implantation procedures.
Emerging markets are showing increased adoption of bioabsorbable stents due to improving healthcare infrastructure and growing medical tourism. Countries in Asia Pacific and Latin America are implementing favorable reimbursement policies for these advanced medical devices. This expansion is supported by increasing healthcare expenditure and rising incidence of cardiovascular diseases in these regions. Market leaders are establishing manufacturing facilities and distribution networks to capitalize on these growth opportunities.
Regulatory Landscape and Standardization
Regulatory bodies are implementing stricter guidelines for bioabsorbable stent approval, requiring comprehensive clinical trials and long-term safety data. The FDA and EMA have established clearer pathways for market authorization, focusing on long-term performance and biodegradation characteristics. This has led to increased R&D investments by key players to meet these evolving regulatory requirements, ensuring patient safety while maintaining market competitiveness.
Regional Analysis: Bioabsorbable Stents MarketEurope
Europe maintains excellent market access through centralized regulatory approval and national reimbursement systems. Countries like Germany, France, and the UK have established interventional cardiology programs that facilitate adoption. The EU's regulatory harmonization enables efficient market entry while maintaining safety standards. Cross-border collaboration between medical centers enables best practice sharing. Pricing and reimbursement mechanisms ensure appropriate utilization, while aging populations provide sustained demand. Medical training programs produce skilled interventional cardiologists who drive appropriate adoption.
Asia-Pacific
The Asia-Pacific region experiences explosive growth due to improving economic conditions and healthcare investment. Countries like Japan, South Korea, and Australia serve as early adopters with sophisticated regulatory systems. China and India show massive potential due to population size and increasing cardiovascular disease prevalence. Medical tourism destinations like Thailand and Singapore attract patients seeking advanced treatments. Regional partnerships and technology transfer agreements accelerate market development while local manufacturing initiatives improve accessibility and affordability across diverse markets.
South America
South America shows regional variation with stronger markets in Brazil, Argentina, and Chile where healthcare systems are more developed. These countries benefit from specialist training programs and growing private healthcare sectors that drive adoption. Regional cooperation through organizations like PAHO facilitates knowledge sharing. Economic challenges sometimes limit public sector investment, but private healthcare shows strong growth. Local manufacturing initiatives in Brazil and Argentina help reduce costs while international partnerships bring technical expertise and training opportunities.
Middle East & Africa
The Middle East shows strong growth in Gulf states where healthcare investment is substantial and international partnerships are common. Countries like Saudi Arabia, UAE, and Qatar attract global experts while developing local expertise. Africa shows slower growth with concentration in major urban centers and private healthcare. South Africa serves as regional hub with established infrastructure. International partnerships and nonprofit initiatives address access challenges while creating sustainable growth models. The region shows long-term potential as healthcare infrastructure develops and economic conditions improve.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global bioabsorbable stents market was valued at US$ 1299 million in 2024 and is expected to reach US$ 7018 million by 2031.
Which key companies operate in Global Bioabsorbable Stents Market?
-> Key players include Abbott Vascular, Boston Scientific, Kyoto Medical Planning Co., Ltd, Elixir, and Arterial Remodeling Technologies, among others.
-> Key growth drivers include cardiovascular disease prevalence, technological advancements, and increasing healthcare expenditure.
-> North America is the largest market, accounting for about 93% market share. Europe is the second largest market with about 2% market share.
-> Emerging trends include bioresorbable scaffold technology, drug-eluting stents, and minimally invasive procedures.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates